increasing role in predicting ADMET properties of candidate compounds, and systematic analysis of experimental and computational data to derive meaningful structure-activity relationships leading to the creation of drug candidates. Finally, candidate drug or lead optimization computational methods are gaining increasing popularity due to advent of GPU coding and advances in the underlying scientific methods (more accurate force fields and sampling algorithms). Janssen, Bayer, and Pfizer already published in 2016 several prospective applications of relative binding affinity free energy calculations, which are now becoming accessible to the lead optimization of the drug discovery process.
We are already beginning to see an upturn in prospective applications showing that in silico approaches can indeed accelerate the pace of drug discovery efforts, and expect this trend to continue in the immediate future, using novel methodologies as we move forward such as machine learning, neural networks, and deep learning.
One of the developers of new technologies for molecular modeling is Dr. Rommie Amaro, an Associate Professor of Chemistry and Biochemistry in University of California, San Diego and the Director of the National Biomedical Computation Resource. Her work is highlighted in this issue's Profile of an Early-career Researcher.
In this issue's Career Forum, we are pleased to offer some thoughts from Christopher I. Bayly Ph.D., Senior Scientist with OpenEye Scientific Software on how his interests led him to a career in computational chemistry.
Updates from the 2017 AACR Annual Meeting and other items
The 2017 AACR Annual Meeting featured over 6,400 abstracts and over 21,900 participants from more than 80 countries. The CICR Working Group sponsored a number of sessions, which are detailed in the News from the CICR Steering Committee section of the newsletter. The CICR Town Hall Meeting on Sunday evening was well attended, with 100 members attending the presentation by CICR leadership and the reception following. Outgoing CICR Chair Dr. Steve Davidsen provided an update on the 2016 activities and accomplishments outlined in the February 2017 Newsletter, followed by a brief update from the Newsletter Editors and an outline by incoming CICR Chair Dr. Melissa Vasbinder of planned CICR activities for the coming year. For those unable to attend, a summary of these plans are in the News from the CICR Steering Committee section below. Pictures of the event can be viewed here. Thanks to everyone who offered suggestions and encouragement to the Newsletter editors during the reception.
The Editors welcome Dr. Jordan L. Meier to the newsletter team as our newest member of the CICR Editorial Board. Dr. Meier has graciously volunteered to fill an open slot on the board for the remainder of 2017, and we look forward to his participation.
Finally, as part of the ongoing effort to provide content of interest to the CICR membership, we are undertaking an initiative with the editors of the AACR journal Molecular Cancer Therapeutics to heighten awareness of the journal among CICR members. For our first installment, we highlight this article summary provided by the editors of MCT. Keep your eyes open for future content.
From Molecular Cancer Therapeutics:
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells Ho-June Lee, Yi Cao, Victoria Pham, Elizabeth Blackwood, Catherine Wilson, Marie Evangelista, Christiaan Klijn, David Stokoe and Jeff Settleman About the Article Using high-throughput profiling of cancer cell lines with candidate anti-cancer agents, Lee and colleagues identified determinants of the response to inhibitors of the Chk1 kinase, a mediator of the DNA damage response. While sensitivity to Chk1 inhibition was previously linked to p53 mutation status, these new findings revealed an unexpected requirement for Chk1 in cells experiencing genotoxic stress after Ras-MEK pathway activation. Chk1 inhibition combined with DNAtargeted chemotherapeutics led to enhanced cell killing in some osteosarcoma, ovarian, and breast cancer cells. These findings provide insight on how to improve the efficacy of Chk1 inhibition in a subpopulation of patients. DOI: 10.1158 /1535 -7163.MCT-16-0504 Published April 2017 Learn more about Molecular Cancer Therapeutics, the AACR journal that specializes in the discovery and development of cancer therapeutics.
Selected Research Highlights
Perspectives Article "The evolution of drug design at Merck Research Laboratories" Frank K. Brown, Edward C. Sherer, Scott A. Johnson, M. Katharine Holloway and Bradley S. Sherborne J. Comput. Aided Mol. Des., 2017 , 31, 255-266. doi: 10.1007 This perspectives article describes the evolution and expansion of Merck's drug design function over the period from 2010-2016. The authors point out the potential benefits achievable by applying a "design first" approach beyond the past efforts to inform small molecule optimization to encompass all phases of the discovery process from lead identification to first in human. The importance of improving human, organizational and technical factors is emphasized. Although the implementation and organizational details differ, the "design first" approach has become prevalent in most major pharma organizations. This perspective offers a useful overview for those interested in an introduction to the application of calculations, modelling and data analysis to contemporary drug discovery.
"Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations" Matteo Aldeghi, Alexander Heifetz, Michael J. Bodkin, Stefan Knapp and Philip C. Biggin J. Am. Chem. Soc., 2017 , 139, 946-957. DOI: 10.1021 Achieving binding selectivity within a protein family is a long-standing challenge in Drug Discovery. Likewise, attempts to understand, predict and design for selectivity has long been an area of intense effort for the modelling and design community. This recent paper describes an effort to apply contemporary Molecular Dynamics approaches to Free Energy calculations to the binding of small molecule bromodomain inhibitors to multiple bromodomains, with comparisons of the calculated values to experimental data. Encouraging agreement of the calculated and experimental results was obtained for a set of three inhibitors for binding to 7 of the 8 bromodomains of the BET-family of proteins. A more challenging effort to calculate affinity of the broad-spectrum inhibitor bromosporine to 22 more structurally diverse bromodomains showed a reduced concordance with experimental data, although reparameterization of the values used for the sulfonamide moiety present in bromosporine improved the agreement somewhat. The authors feel that these results are encouraging, and that the approach should be examined for additional families of protein targets. Preliminary data reported at the 2017 annual meeting of the AACR by Wang and co-workers from the University of North Carolina Lineberger Comprehensive Cancer Center (Abstract 978) suggests that the efficacy of immunotherapy drugs can be further enhanced via the use of nanoparticles. This preclinical work utilized a nanoparticle to co-deliver a checkpoint inhibitor and an investigational OX40 agonist into T-cells. This co-delivery had the effect of increasing T-cell stimulation and resulted in corresponding increases in preclinical survival rates. Initiating the degradation of intracellular proteins with chimeric small molecules that combine a high affinity ligand to a protein of interest along with a small molecule that is capable of recruiting an E3 ligase has become a new area of extremely high interest in medicinal chemistry. In a recent paper in the Journal of Medicinal Chemistry, Jung and co-workers describe this PROTAC (Proteolysis Targeting Chimera) approach to the Sirt2 protein. This work utilizes a thalidomide derivative that is known to recruit the Cereblon E3 ligase and a recently identified Sirt2 inhibitor from the authors' lab. Their chimeric compound induces the degradation of Sirt2 in HeLa cancer cell lines and is believed to be the first reported example of targeting an epigenetic eraser protein with this degradation strategy. One of the challenges with this approach is the design and synthesis of the linker that establishes the chimeric bifunctional combination of the two small molecules. Notably, the authors employ in this work a "click" chemistry strategy to assemble the chimeric linker, thus creating a thalidomide conjugate that can conceivably be utilized for a number of other ligands for other target proteins of interest. Protein phosphorylation is an important post-translational modification that plays a variety of critical roles in cellular function. In this manuscript, Francavilla et al. reported the application of single-shot mass spectrometry-based phosphoproteomics to primary cells created from tiny tissue biopsy samples from epithelial ovarian cancer. The proteome and phosphoproteome was studied in ex vivo cultured cells and expression levels of proteins and phosphorylation sites were compared from patient-matched epithelial ovarian cancer versus healthy cells (ovarian surface epithelium and fallopian tube epithelium). Complementary information was obtained from protein and phosphosite expression levels in developing a tissue specific signature. Particular proteins of interest were further confirmed by western blot and immunohistochemistry on tissue microarrays. Kinase signatures were also developed for epithelial ovarian cancer. CDK7 targets were shown to be especially important in controlling epithelial ovarian cancer cell proliferation in primary and ovarian cancer cell lines. Inhibition of CDK7 was also demonstrated to repress proliferation of epithelial ovarian cancer cells. This study provides a substantial contribution of information to the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) database, and suggests the utility of phosphoproteomics for identifying novel druggable pathways in cancer. Next-generation genomic sequencing has the promise to identify opportunities in cancer to drug aberrancies in the genome for personalized medicine. However, the concept of the druggable genome largely assumes that the genome is reflected in the downstream proteome which is the primary drug target. It is reasonable to assume that the direct study of the proteome provides opportunities to validate genomic aberrations, as well as to identify new opportunities for targeted therapies. Huang et al. recently conducted such a proteogenomic study of 24 breast cancer patient-derived xenograft mouse models. Integrated analysis of protein and gene-expression data revealed gene expression signatures were well correlated with non-stromal protein expression. The integrated analysis also confirmed predicted genomic targets in a variety of receptor tyrosine kinases. Proteomic and phosphoproteomic findings also revealed novel signatures that were not reflected in the genomic profiling, suggesting novel druggable opportunities. Further drug treatment experiments supported identified response predictions.
"Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in
This study demonstrates the complementary information that can be obtained by both genomic and proteomic studies, and the utility of proteomic analysis in cancer. A blood-based test for cancer early detection remains the Holy Grail for diagnostics. Protein phosphorylation is well known to play a critical role in regulating cellular function and is postulated to be important in early cancer. Despite the known importance of phosphorylation, relatively few studies have exploited the biological modification for diagnostic purposes. In this recent paper, Chen et al. describe a strategy to study phosphoproteins in extracellular vesicles isolated from human plasma. In recent years, extracellular vesicles have gained much attention as a means of transporting molecular information from cancer cells in blood circulation. Approximately 10,000 unique phosphopeptides were identified in extracellular vesicles isolated from cancer patient plasma samples. A subset of 144 phosphoproteins had increased levels in breast cancer patients compared to healthy controls. Some candidate biomarkers were further validated by parallel reaction monitoring. This study suggests that phosphoproteins in extracellular vesicles may have promise in cancer diagnostics. A new allosteric small-molecule inhibitor of BCR-ABL1 is described, asciminib (ABL001). Unlike other inhibitors which are ATP competitive and bind to the catalytic site, ABL001 binds to the myristoyl pocket of BCL-ABL1 inducing the formation of an inactive kinase conformation. Although ABL001 has a similar cellular potency to second generation catalytic inhibitors, it contains a different spectrum of activity against various BCR-ABL1 resistance mutations. ABL001 is active against all known catalytic site mutations (including Thr315Ile) while catalytic site inhibitors are active against myristyl-site mutations. Such a pattern of non-overlapping resistance profiles was thought to provide a perfect test for the hypothesis that such a drug pair might prevent the emergence of resistant disease. Crystallography indicates that ABL001 and nilotinib can co-bind to a single BCR-ABL1 molecule. Furthermore, in vitro cellular studies show the additive effects of ABL001 in combination with nilotinib, imatinib or dasatinib. In a CML xenograft study, the combination of ABL001 and nilotinib led to complete disease control and eradicated the tumor. Unlike single agent dosing of either agent, no resistance emerged during or after the cessation of treatment. These results offer the possibility of treatment-free remission for CML patients and clinical trials with ABL001 in combination with nilotinib, imatinib and dasatinib are ongoing.
"Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells" The authors found three FDA approved targeted therapies, used in the treatment of B-cell driven tumors, unexpectedly increased DNA damage in both normal and tumor cells. In particular, PI3Kδ inhibitors idelalisib (Zydelig), duvelisib and ibrutinib (Imbruvica) increase genomic instability in B-cells by affecting the expression of activation-induced cytidine deaminase (AID), a B-cell specific enzyme. While idelalisib and duvelisib directly inhibit PI3Kδ, ibrutinib inhibits BTK, which is thought to support PI3Kδ activity through a large multiprotein complex. AID is normally only expressed in immune response activated B-cells and the enzyme action is targeted at immunoglobulin genes to initiate class switch recombination and somatic hypermutation. Both idelalisib and duvelisib increase AID expression in activated B-cells leading to a higher number of ontarget mutations. However, in vitro treatment also resulted in a higher frequency of off-target mutations, a situation which may lead to the development of certain human B-cell tumors. The authors performed in vivo experiments which showed that all three drugs increased the development of AID-dependent B-cell tumors, in a mouse model. Studies of blood obtained from CLL patients before and after treatment with idelalisib showed increased mutational levels by AID. All three drugs were recently approved and are given to patients indefinitely raising the need for follow-up of patients to see whether the mouse results are also observed in the clinic. These results show the potential for a targeted therapy to cause the same mutagenic DNA damage that occurs with some classic chemotherapeutic strategies. Rommie's scientific interests lie at the intersection of computer-aided drug discovery and biophysical simulation methods. She has a long-standing interest in incorporating structural and dynamical information derived from all-atom molecular dynamics simulations in drug discovery programs, and has worked in a variety of disease areas, including infectious diseases and cancer. Her lab's work on p53 revealed a novel druggable pocket that clarified the mechanism of action for a compound in clinical trials; this work served as the basis for the formation of a start-up company related to the development of p53 reactivation drugs, Actavalon, Inc. Rommie is a co-founder, on the scientific advisory board, and an equity shareholder in Actavalon, Inc.
Her scientific vision revolves around the continued development of molecular dynamics simulations in drug discovery programs, particularly in expanding the range and complexity of molecular constituents represented in such simulations, and novel multiscale methods for elucidating their time dependent dynamics. She is the Director of the NIH P41 National Biomedical Computation Resource and a co-Director of the NIH U01 Drug Design Data Resource.
Rommie is the recipient of an NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, the ACS COMP OpenEye Outstanding Junior Faculty Award, the ACS Kavli Foundation Emerging Leader in Chemistry National Lecturer, and the 2016 Corwin Hansch Award.
Spotlight on World News
The American Chemical Society establishes a new framework for reporting possible assay interference compounds.
In an editorial shared across several journals sponsored by the American Chemical Society (ACS), a joint panel of the journals' Editors-in-Chief clarified and publicized the stance of the organization on the reporting of compounds that may interfere in assays for a variety of reasons. It has become well known in the chemical literature that screening hits and other compounds can display misleading activity in a wide range of biochemical assays. These interference mechanisms can include unexpected redox activity, spectroscopic interference, and colloidal aggregation, among other reasons. In this communication, the editors outline several of these mechanisms and common methods by which such interference can be detected. Further, they state a revised policy in which any author reporting results in one of the ACS journals will be required to detail an analysis of active compounds from any source against lists of known inhibitors and to provide multiple pieces of experimental evidence that establish that the reported data for potentially interfering compounds is in line with expectations and not a result of artifactual activity. Read the related blogpost.
Warp Drive Bio and GSK team up to tackle difficult targets Warp Drive Bio and GlaxoSmithKline (GSK) recently announced a new collaboration that will combine elements of both companies' technology to discover drugs against "undruggable" targets of high potential value in cancer and other diseases. The intent is to use the GSK Encoded Library Technology (ELT) to create a library containing up to 200 million compounds based on Warp Drive's Small Molecule-Assisted Receptor Targeting (SMART™) technology. This enormous new collection may have promise for discovering leads for conventionally intractable drug targets, as the SMART™ compounds rely on binding to an intracellular receptor that can then bind to a protein without a traditional small molecule binding site. In effect, this would commandeer an intracellular protein to create, in situ, a tailored biologic agent that would be capable of affecting the target protein. Initial targets are expected to center on the Ras protein, as well as SHP2 and Cbl-b. On March 23, 2017, the PD-L1 targeting human monoclonal antibody avelumab (EMD Serono) was approved for metastatic Merkel cell carcinoma (MCC). This is the first FDA-approved treatment for metastatic MCC, a rare and aggressive skin cancer. The compound is also being evaluated in a various investigational clinical trials including for other indications including non-small cell lung cancer (NSCLC), bladder, breast and renal cell carcinoma (RCC). Avelumab joins the other FDAapproved PD/PD-L1 approved antibodies in this competitive space including pembrolizumab (Merck, 2014 ), nivolumab (Bristol-Myers Squibb, 2014 and atezolizumab (Roche Genentech, 2016) . See related blogpost. For the 2017-2018 term, our CICR working group will continue making progress around expanding our outreach by increasing geographic diversity within CICR, and ensuring that CICR members have opportunities to connect with chemists outside of the annual AACR meetings. We are pleased that within our CICR Steering Committee we have representation from the US, Europe, Asia, and Australasia and we plan to capitalize on our ties within each of these regions to help drive our outreach efforts. We are working on plans to increase the chemistry presence at the AACR-NCI-EORTC International Symposium on Molecular Targets & Cancer Therapeutics meeting as well as the New Horizons in Cancer Research Conference. We are also working on proposals for a CICR special conference that would provide an additional venue for chemists to meet and share science and will be looking for input and volunteers from the CICR community as we move forward.
As part of our outreach efforts, we also aim to provide support to early-career researchers through sponsoring CICR scholar-in-training awards. The award would provide the funds necessary for the next generation of chemistry researchers to attend the AACR Annual Meeting. We are particularly interested in fostering attendance from scientists in related research areas, as well as researchers from outside of the USA who would not normally attend the AACR Annual Meeting. We are happy to help to direct any inquiries around sponsorship opportunities to the appropriate individuals within AACR. We will also be continuing to progress initiatives that were started under the leadership of Drs. Uehling and Davidsen focused on the optimal use of chemical probes and sharing academia/industry collaboration best practices.
We encourage any CICR members interested in contributing to any of the plans outlined above to reach out to either myself, Steve, or Julian below and we can provide you with more information and opportunities to get involved. We also encourage all CICR members to urge your colleagues to join the CICR Working Group in order to increase our leverage and influence within AACR. We appreciate all ideas and input to driving our chemistry vision within AACR and look forward to hearing from you. 
